Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phthalic Acids | 10 | 2023 | 40 | 4.610 |
Why?
|
| Breast Neoplasms | 25 | 2025 | 1211 | 4.450 |
Why?
|
| Postmenopause | 20 | 2025 | 238 | 4.140 |
Why?
|
| Environmental Pollutants | 8 | 2025 | 95 | 3.200 |
Why?
|
| Women's Health | 14 | 2022 | 374 | 2.340 |
Why?
|
| Antidepressive Agents | 5 | 2018 | 226 | 1.860 |
Why?
|
| Environmental Exposure | 8 | 2025 | 220 | 1.660 |
Why?
|
| Biomarkers | 9 | 2023 | 1431 | 1.640 |
Why?
|
| Breast | 6 | 2025 | 190 | 1.640 |
Why?
|
| Mammography | 11 | 2019 | 290 | 1.610 |
Why?
|
| Benzhydryl Compounds | 3 | 2018 | 61 | 1.440 |
Why?
|
| Phenols | 3 | 2018 | 82 | 1.420 |
Why?
|
| Endometrial Neoplasms | 5 | 2019 | 64 | 1.240 |
Why?
|
| Endocrine Disruptors | 2 | 2021 | 79 | 1.180 |
Why?
|
| Fluorocarbons | 2 | 2025 | 44 | 1.110 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2022 | 66 | 1.060 |
Why?
|
| Prospective Studies | 25 | 2025 | 3315 | 1.050 |
Why?
|
| Mammary Glands, Human | 3 | 2025 | 55 | 1.040 |
Why?
|
| Female | 58 | 2025 | 33351 | 1.020 |
Why?
|
| Aged | 39 | 2025 | 14648 | 1.000 |
Why?
|
| Middle Aged | 44 | 2025 | 17899 | 0.990 |
Why?
|
| Risk Factors | 26 | 2025 | 5339 | 0.950 |
Why?
|
| Body Mass Index | 11 | 2025 | 872 | 0.900 |
Why?
|
| Case-Control Studies | 10 | 2022 | 1130 | 0.870 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 120 | 0.850 |
Why?
|
| Bone Density | 3 | 2022 | 137 | 0.800 |
Why?
|
| Humans | 64 | 2025 | 64243 | 0.800 |
Why?
|
| Adiposity | 1 | 2023 | 83 | 0.740 |
Why?
|
| Sleep | 2 | 2016 | 231 | 0.690 |
Why?
|
| Depression | 3 | 2017 | 909 | 0.660 |
Why?
|
| Job Application | 2 | 2021 | 7 | 0.650 |
Why?
|
| Environmental Monitoring | 3 | 2016 | 149 | 0.640 |
Why?
|
| Suicide | 1 | 2022 | 134 | 0.630 |
Why?
|
| Osteoporotic Fractures | 3 | 2021 | 36 | 0.630 |
Why?
|
| Menopause | 5 | 2022 | 260 | 0.630 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2019 | 3 | 0.630 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1272 | 0.620 |
Why?
|
| Hot Flashes | 3 | 2021 | 101 | 0.620 |
Why?
|
| Medical Oncology | 2 | 2021 | 68 | 0.620 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 44 | 0.610 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 165 | 0.590 |
Why?
|
| United States | 19 | 2019 | 7923 | 0.590 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 82 | 0.590 |
Why?
|
| Weight Gain | 2 | 2022 | 168 | 0.580 |
Why?
|
| Premenopause | 4 | 2022 | 61 | 0.570 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 2478 | 0.570 |
Why?
|
| Depressive Disorder | 2 | 2018 | 286 | 0.570 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 2616 | 0.570 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 276 | 0.560 |
Why?
|
| Vasomotor System | 1 | 2018 | 23 | 0.550 |
Why?
|
| Sweating | 1 | 2016 | 27 | 0.500 |
Why?
|
| Prolactin | 1 | 2016 | 40 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 145 | 0.480 |
Why?
|
| Obesity | 6 | 2025 | 1247 | 0.480 |
Why?
|
| Body Composition | 1 | 2016 | 153 | 0.480 |
Why?
|
| Incidence | 8 | 2025 | 1383 | 0.480 |
Why?
|
| Cancer Survivors | 1 | 2018 | 120 | 0.480 |
Why?
|
| Negotiating | 1 | 2016 | 16 | 0.470 |
Why?
|
| Coffee | 2 | 2015 | 18 | 0.470 |
Why?
|
| Metabolic Syndrome | 2 | 2019 | 142 | 0.460 |
Why?
|
| Adult | 20 | 2025 | 17117 | 0.460 |
Why?
|
| Personnel Selection | 1 | 2016 | 56 | 0.450 |
Why?
|
| Research Personnel | 1 | 2016 | 94 | 0.450 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 160 | 0.440 |
Why?
|
| Interviews as Topic | 2 | 2016 | 539 | 0.410 |
Why?
|
| Intra-Abdominal Fat | 2 | 2025 | 35 | 0.410 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 735 | 0.380 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 666 | 0.380 |
Why?
|
| Cohort Studies | 9 | 2019 | 2604 | 0.370 |
Why?
|
| Risk-Taking | 1 | 2012 | 162 | 0.350 |
Why?
|
| Melatonin | 3 | 2018 | 67 | 0.350 |
Why?
|
| Caffeine | 1 | 2011 | 46 | 0.350 |
Why?
|
| Prognosis | 4 | 2018 | 1769 | 0.350 |
Why?
|
| Absorptiometry, Photon | 3 | 2025 | 76 | 0.350 |
Why?
|
| Densitometry | 1 | 2011 | 13 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 65 | 0.340 |
Why?
|
| Data Collection | 2 | 2019 | 384 | 0.340 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 146 | 0.340 |
Why?
|
| Creatinine | 2 | 2021 | 133 | 0.320 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 194 | 0.320 |
Why?
|
| Inflammation | 2 | 2021 | 1162 | 0.310 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2021 | 81 | 0.300 |
Why?
|
| Caregivers | 1 | 2012 | 283 | 0.300 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 321 | 0.300 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 848 | 0.290 |
Why?
|
| Osteoporosis | 2 | 2013 | 108 | 0.270 |
Why?
|
| Breast Feeding | 2 | 2021 | 153 | 0.270 |
Why?
|
| Recreation | 1 | 2007 | 21 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 215 | 0.260 |
Why?
|
| Community Pharmacy Services | 2 | 2019 | 13 | 0.250 |
Why?
|
| Hip Fractures | 1 | 2007 | 77 | 0.240 |
Why?
|
| Survivors | 1 | 2007 | 182 | 0.240 |
Why?
|
| Diet | 3 | 2015 | 533 | 0.240 |
Why?
|
| Poverty | 2 | 2013 | 299 | 0.230 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 144 | 0.230 |
Why?
|
| Linear Models | 4 | 2015 | 407 | 0.220 |
Why?
|
| Health Education | 1 | 2006 | 190 | 0.220 |
Why?
|
| Odds Ratio | 4 | 2019 | 759 | 0.220 |
Why?
|
| Fetal Blood | 1 | 2025 | 73 | 0.220 |
Why?
|
| Rural Population | 1 | 2006 | 212 | 0.220 |
Why?
|
| Subcutaneous Fat | 1 | 2025 | 47 | 0.220 |
Why?
|
| Motor Activity | 1 | 2007 | 346 | 0.210 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 529 | 0.210 |
Why?
|
| Self Report | 2 | 2016 | 388 | 0.210 |
Why?
|
| Risk Assessment | 7 | 2019 | 2046 | 0.210 |
Why?
|
| Talc | 2 | 2014 | 5 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2018 | 771 | 0.200 |
Why?
|
| Autistic Disorder | 1 | 2025 | 147 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 5520 | 0.180 |
Why?
|
| Pregnancy | 5 | 2025 | 2370 | 0.180 |
Why?
|
| Health Promotion | 1 | 2006 | 505 | 0.180 |
Why?
|
| Autism Spectrum Disorder | 1 | 2025 | 180 | 0.180 |
Why?
|
| Femur Neck | 1 | 2021 | 12 | 0.180 |
Why?
|
| Pelvic Bones | 1 | 2021 | 17 | 0.170 |
Why?
|
| Parity | 1 | 2021 | 71 | 0.170 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2021 | 48 | 0.170 |
Why?
|
| Logistic Models | 3 | 2016 | 1270 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2015 | 2737 | 0.160 |
Why?
|
| Pharmacists | 2 | 2019 | 129 | 0.160 |
Why?
|
| Culture | 2 | 2018 | 80 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 21 | 0.150 |
Why?
|
| Pharmacies | 1 | 2019 | 36 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2021 | 200 | 0.150 |
Why?
|
| Anthropometry | 2 | 2009 | 85 | 0.150 |
Why?
|
| Body Weight | 2 | 2011 | 379 | 0.140 |
Why?
|
| Women | 1 | 2018 | 44 | 0.140 |
Why?
|
| Mastectomy | 1 | 2018 | 55 | 0.140 |
Why?
|
| Young Adult | 4 | 2016 | 4776 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 230 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2018 | 103 | 0.140 |
Why?
|
| Maternal Behavior | 1 | 2018 | 31 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 147 | 0.130 |
Why?
|
| Time Factors | 5 | 2018 | 3724 | 0.130 |
Why?
|
| Child | 3 | 2025 | 4583 | 0.120 |
Why?
|
| Adolescent | 5 | 2023 | 6304 | 0.120 |
Why?
|
| Hypertension | 2 | 2019 | 593 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 512 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2019 | 368 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 161 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 102 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2018 | 296 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 379 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2018 | 517 | 0.120 |
Why?
|
| Tea | 1 | 2015 | 32 | 0.110 |
Why?
|
| Health Surveys | 1 | 2016 | 314 | 0.110 |
Why?
|
| Perineum | 1 | 2014 | 19 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 2217 | 0.110 |
Why?
|
| Folic Acid | 1 | 2014 | 42 | 0.100 |
Why?
|
| Fatty Acids, Essential | 1 | 2013 | 8 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2014 | 65 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2016 | 381 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 264 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2013 | 6 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 155 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 930 | 0.100 |
Why?
|
| Health Services Accessibility | 3 | 2008 | 575 | 0.100 |
Why?
|
| Age Factors | 2 | 2014 | 1569 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 39 | 0.090 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2012 | 44 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2012 | 58 | 0.090 |
Why?
|
| Male | 7 | 2025 | 30295 | 0.090 |
Why?
|
| Time | 1 | 2012 | 30 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2013 | 202 | 0.090 |
Why?
|
| Physical Examination | 1 | 2012 | 111 | 0.090 |
Why?
|
| Health Literacy | 1 | 2013 | 86 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2013 | 150 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2011 | 44 | 0.090 |
Why?
|
| Melanoma | 1 | 2015 | 331 | 0.090 |
Why?
|
| Smoking | 2 | 2007 | 861 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 478 | 0.090 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 12 | 0.090 |
Why?
|
| Minority Groups | 2 | 2013 | 141 | 0.090 |
Why?
|
| Soybean Proteins | 1 | 2011 | 20 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 85 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 410 | 0.080 |
Why?
|
| North Carolina | 2 | 2007 | 74 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1681 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 166 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2010 | 324 | 0.070 |
Why?
|
| Asthma | 1 | 2014 | 471 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 17 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 30 | 0.070 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 85 | 0.070 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 28 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 726 | 0.070 |
Why?
|
| Testosterone | 1 | 2008 | 121 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 141 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 616 | 0.070 |
Why?
|
| Estradiol | 1 | 2008 | 258 | 0.070 |
Why?
|
| Body Height | 1 | 2007 | 66 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2008 | 144 | 0.060 |
Why?
|
| Age Distribution | 1 | 2007 | 258 | 0.060 |
Why?
|
| Mass Screening | 2 | 2008 | 693 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 487 | 0.060 |
Why?
|
| Colonic Polyps | 1 | 2005 | 24 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 71 | 0.060 |
Why?
|
| Singapore | 1 | 2025 | 14 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 859 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2005 | 99 | 0.050 |
Why?
|
| Breast Density | 2 | 2015 | 17 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 788 | 0.050 |
Why?
|
| Amygdala | 1 | 2023 | 84 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 489 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 407 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 133 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 45 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2019 | 37 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6726 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 270 | 0.030 |
Why?
|
| Communication Barriers | 1 | 2018 | 68 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 222 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 142 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5691 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 33 | 0.030 |
Why?
|
| Powders | 1 | 2014 | 20 | 0.030 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 15 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1407 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 63 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2014 | 42 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1118 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1375 | 0.030 |
Why?
|
| Minority Health | 1 | 2013 | 6 | 0.020 |
Why?
|
| Urban Health | 1 | 2013 | 41 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 1664 | 0.020 |
Why?
|
| Cities | 1 | 2013 | 31 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 35 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 17 | 0.020 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 32 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 158 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 198 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 123 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 239 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 163 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2008 | 56 | 0.020 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2007 | 57 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2007 | 15 | 0.020 |
Why?
|
| Indians, North American | 1 | 2007 | 29 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 278 | 0.020 |
Why?
|
| Smoking Prevention | 1 | 2007 | 162 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 412 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2007 | 128 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 221 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 34 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 89 | 0.010 |
Why?
|
| Adenoma | 1 | 2005 | 67 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2005 | 95 | 0.010 |
Why?
|
| Perception | 1 | 2005 | 178 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 650 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 551 | 0.010 |
Why?
|